(ABL) is a global contract development and manufacturing organization (CDMO) providing clinical supply solutions for vaccines, immunotherapies, oncolytic and genetic therapy agents, and other large molecule products. They have invested in the iCELLis bioreactor technology and are now demonstrating their use of the technology for lentivirus production at the typical production scale for CAR-T applications. ABL’s goal is to help customers reach the market quickly and efficiently with the iCELLis bioreactor.